Clinical Trial

A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors

Name: A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors — clinical trial record (NCT07016490)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and anti-tumor activity of SSGJ-709 as a single agent in patients with advanced malignancies.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-06-04; most recent amendment 2026-01-26.

Trial Details

NCT Number	NCT07016490
Lead Sponsor	Shenyang Sunshine Pharmaceutical Co., LTD. Collaborators: Macquarie University, Australia
Conditions	Advanced Malignant Tumors
Enrollment	15 participants
Start Date	2025-06-12
Primary Completion	2027-09-30 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-28